Associated Genetic Biomarkers
GATA binding protein 2 (GATA2) is a gene that encodes a zinc-finger transcription factor in the GATA family. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions and insertions are observed in cancers such as colorectal cancer, lung cancer, and skin cancer.
GATA2 is altered in 1.13% of all cancers with colon adenocarcinoma, lung adenocarcinoma, acute myeloid leukemia, prostate adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in GATA2 are GATA2 Mutation (0.84%), GATA2 Exon 3 Mutation (0.37%), GATA2 Amplification (0.16%), GATA2 Exon 5 Mutation (0.13%), and GATA2 Exon 4 Mutation (0.11%) .
GATA2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains GATA2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with GATA2 status in the inclusion eligibility criteria most commonly target acute myeloid leukemia, myelodysplastic syndrome with excess blasts-2, and myeloid neoplasm .
The most frequent alterations to serve as inclusion eligibility criteria are GATA2 Exon 3 Mutation, GATA2 Exon 4 Mutation, and GATA2 Exon 5 Mutation .
Allogeneic hematopoietic stem cell transplantation and liposome-encapsulated daunorubicin-cytarabine are the most frequent therapies in trials with GATA2 as an inclusion criteria .
Significance of GATA2 in Diseases
Acute Myeloid Leukemia +
Myelodysplastic Syndrome With Excess Blasts-2 +
GATA2 is altered in 2.4% of myelodysplastic syndrome with excess blasts-2 patients .
GATA2 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains GATA2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) .
Myeloid Neoplasm +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.